XLV and IXJ are two healthcare ETFs with different approaches: XLV focuses on 60 U.S. S&P 500 healthcare stocks with a low 0.08% expense ratio and stronger recent returns, while IXJ offers broader global diversification with 110 holdings across multiple countries but charges a higher 0.38% expense ratio. The choice...
The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF that tracks small-cap and mid-cap pharmaceutical and biotechnology stocks in Phase II or Phase III FDA clinical trials. With a 0.5% expense ratio, $243.54 million in assets, and 107 holdings, it has delivered 32.1% year-to-date returns and...
RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and...
The article compares two healthcare sector ETFs: Vanguard Health Care ETF (VHT) with 423 holdings and State Street Health Care Select Sector SPDR ETF (XLV) with 60 holdings. While XLV has slightly lower expenses (0.08% vs 0.09%) and better 5-year returns, VHT outperforms on 1-year returns and offers broader...
State Street's XLV healthcare ETF offers broader exposure with lower costs (0.08% expense ratio) and higher dividend yield (1.6%), delivering 30% more growth over five years with lower volatility. VanEck's BBH biotech ETF provides concentrated exposure to 25 biotech stocks with higher recent returns but greater risk,...
XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk...
The State Street Health Care Select Sector SPDR ETF (XLV) and Fidelity MSCI Health Care Index ETF (FHLC) both offer low-cost healthcare exposure with identical 0.08% expense ratios. XLV focuses on 60 mega-cap healthcare stocks and has delivered stronger 5-year returns ($1,332 vs $1,276 on $1,000 invested), higher...
The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While...
The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount...
The healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise:...
The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's...
AbbVie announced nine-year Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab significantly improved progression-free survival (6.4 years vs 3.2 years) compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients. The fixed-duration combination demonstrated median...
The article compares two healthcare ETFs with different investment strategies: XLV (State Street Health Care Select Sector SPDR ETF) focuses on established healthcare giants with low costs and stable dividends, while PINK (Simplify Health Care ETF) pursues medical innovation through active management and donates...
The Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena,...
State Street's XLV healthcare ETF outperforms Invesco's RSPH with a lower expense ratio (0.08% vs 0.4%), higher dividend yield (1.72% vs 0.7%), and better 5-year returns ($1,311 vs $1,134 on $1,000 invested). XLV uses market-cap weighting favoring large pharmaceutical companies, while RSPH employs equal-weighting for...
AbbVie and Pfizer are compared as dividend-paying pharmaceutical giants facing patent cliffs. AbbVie shows stronger growth with $61.2B revenue (up 8.6%) and successful new product launches offsetting Humira losses, while Pfizer generated $62.6B revenue (down 1.6%) with higher dividend yield but concerns about future...
U.S. stocks declined midday Tuesday as 30-year Treasury yields surged to 19-year highs amid an unresolved U.S.-Iran standoff keeping oil prices elevated. The Nasdaq 100 fell 1%, S&P 500 dropped 0.6%, and Russell 2000 slid 1.3%. Defensive sectors like healthcare and utilities outperformed, while chipmakers and clean...
With the 2026 midterm elections six months away, certain sectors and stocks are positioned to benefit from potential policy shifts. Defense stocks like Lockheed Martin and RTX are expected to see sustained spending on autonomy and AI initiatives. Healthcare stocks, historically outperforming by 17% in midterm years,...
U.S. equities reached fresh record highs on Friday, with the Nasdaq 100 jumping 1.6% above 29,000 and the S&P 500 climbing 0.8% to near 7,400. A strong April jobs report (115,000 jobs added) and a semiconductor rally led gains, with Micron Technology surging 13.5% for its best week since 2008. However, mixed earnings...
Hedge fund billionaire Daniel Loeb's Third Point LLC acquired a stake in Thermo Fisher Scientific (TMO) in Q4 2025, purchasing 50,000 shares. The company reported strong Q1 2026 earnings of $5.44 per share, beating expectations, with 6% YoY revenue growth to $11.01 billion. TMO raised full-year guidance for both...
Headlines via Polygon.io. Links open the original publisher.